Genexine, Inc. (KOSDAQ:095700)
 5,180.00
 +110.00 (2.17%)
  Oct 31, 2025, 3:30 PM KST
Genexine Revenue
Genexine had revenue of 2.07B KRW in the quarter ending March 31, 2024, with 199.63% growth. This brings the company's revenue in the last twelve months to 5.81B, down -3.50% year-over-year. In the year 2023, Genexine had annual revenue of 4.43B, down -72.57%.
Revenue (ttm) 
 5.81B
Revenue Growth 
 -3.50%
P/S Ratio 
 40.56
Revenue / Employee 
 67.53M
Employees 
 86
Market Cap 
235.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2023 | 4.43B | -11.71B | -72.57% | 
| Dec 31, 2022 | 16.14B | -20.69B | -56.18% | 
| Dec 31, 2021 | 36.83B | 18.28B | 98.61% | 
| Dec 31, 2020 | 18.54B | 7.24B | 64.06% | 
| Dec 31, 2019 | 11.30B | 5.05B | 80.80% | 
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |